TACE联合阿帕替尼或微波消融治疗中晚期肝细胞癌现状

TACE combined with apatinib or microwave ablation in treatment of advanced hepatocellular carcinoma

肝细胞癌(HCC)是全球癌症相关死亡最常见的原因之一。对于无法手术切除的HCC,目前多采用以TACE为中心,联合阿帕替尼或微波消融(MWA)的疗法。对于中晚期HCC,TACE联合阿帕替尼或MWA均可明显提高疗效和改善预后,但在联合疗法的应用和其远期疗效上仍存在争议。本文对TACE联合阿帕替尼或MWA治疗中晚期HCC的临床应用、疗效及存在的问题进行综述。

Hepatocellular carcinoma（HCC）is one of the most common causes of cancer-related deaths around the world.For the treatment of unresectable HCC,TACE combined with apatinib or microwave ablation（MWA）is widely used.Although the efficacy and prognosis of advanced HCC can be improved significantly by this way,there are still some controversial issues in the application and long-term efficacy of combination therapy.The clinical application,efficacy and existing problems of TACE combined with apatinib or MWA in treatment of advanced HCC were reviewed in this article.